Microglia and brain macrophages: An update

Neuropathology

Volumn 37, Issue 5, 2017, Pages 452-464

  Sasaki, Atsushi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

DAP12; glioblastoma; Microglia; microgliopathy; tumor associated macrophages

Indexed keywords

COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; MYELIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG;

ARTICLE; AXON; GLIOMA; HEREDITARY LEUKOENCEPHALOPATHY WITH SPHEROIDS; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEUKOENCEPHALOPATHY; MACROPHAGE; MICROGLIA; NASU HAKOLA DISEASE; NEUROPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; BRAIN;

ANIMALS; BRAIN; HUMANS; MACROPHAGES; MICROGLIA;

EID: 85002202439     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12354     Document Type: Article

References (120)

1. Martínez AJ, Sell M, Mitrovics T et al. The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Pathol Res Pract 1995; 191: 427–443. DOI:10.1016/S0344-0338(11)80730-2.
2. Wierzba-Bobrowicz T, Gwiazda E, Kosno-Kruszewska E et al. Morphological analysis of active microglia--rod and ramified microglia in human brains affected by some neurological diseases (SSPE, Alzheimer's disease and Wilson's disease). Folia Neuropathol 2002; 40: 125–131.
3. Hattori M, Hashizume Y, Yoshida M et al. Distribution of astrocytic plaques in the corticobasal degeneration brain and comparison with tuft-shaped astrocytes in the progressive supranuclear palsy brain. Acta Neuropathol 2003; 106: 143–149. DOI:10.1007/s00401-003-0711-4.
4. Nishie M, Mori F, Fujiwara H et al. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol 2004; 107: 292–298. DOI:10.1007/s00401-003-0811-1.
5. del Rio-Hortega P. Notas tecnicas. Coloracion rapida de tejidos normales y patologicos con carbonato de Plata amoniacal. Trab Lab Invest Biol Univ Madrid 1919; 17: 29–235.
6. del Rio-Hortega P. Microglia. In: Penfield W, ed. Cytology and Cellular Pathology of the Nervous System, vol. II. New York: Hoeber, 1932; 481–534.
7. Graeber MB, Scheithauer BW, Kreutzberg GW. Microglia in brain tumors. Glia 2002; 40: 252–259. DOI:10.1002/glia.10147.
8. Graeber MB, Blakemore WF, Kreutzberg GW. Cellular pathology of the central nervous system. In: Graham DI, Lantos PL, eds. Greenfield's Neuropathology, 7th edn, chap 3. London: Edward Arnold, 2002; 123–191.
9. Liu GJ, Middleton RJ, Hatty CR et al. The 18 kDa translocator protein, microglia and neuroinflammation. Brain Pathol 2014; 24: 631–653. DOI:10.1111/bpa.12196.
10. Ginhoux F, Greter M, Leboeuf M et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010; 330: 841–845. DOI:10.1126/science.1194637.
11. Rademakers R, Baker M, Nicholson AM et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet 2012; 44: 200–205. DOI:10.1038/ng.1027.
12. Schuberth M, Levin J, Sawalhe D et al. [Hereditary diffuse leukencephalopathy with spheroids: a microgliopathy due to CSF1 receptor impairment] [article in German]. Nervenarzt 2014; 85: 465–470. DOI:10.1007/s00115-014-4052-4.
13. Paloneva J, Kestilä M, Wu J et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 2000; 25: 357–361. DOI:10.1038/77153.
14. Paloneva J, Manninen T, Christman G et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 2002; 71: 656–662. DOI:10.1086/342259.
15. De Jager PL, Jia X, Wang JX et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776–782. DOI:10.1038/ng.401.
16. International Multiple Sclerosis Genetics Consortium. The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case–control study. PLOS ONE 2011; 6: e18813. DOI:10.1371/journal.pone.0018813.
17. Derecki NC, Cronk JC, Lu Z et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012; 484: 105–109. DOI:10.1038/nature10907.
18. Hulette CM. Microglioma, a histiocytic neoplasm of the central nervous system. Mod Pathol 1996; 9: 316–319.
19. Mathews A, Ohsawa K, Buckland ME et al. Microglioma in a child – a further case in support of the microglioma entity and distinction from histiocytic sarcoma. Clin Neuropathol 2016; 35: 302–313. DOI:10.5414/NP300938.
20. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 2014; 105: 1–8. DOI:10.1111/cas.12314.
21. Lahmar Q, Keirsse J, Laoui D, Movahedi K, Van Overmeire E, Van Ginderachter JA. Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim Biophys Acta 1865; 2016: 23–34. DOI:10.1016/j.bbcan.2015.06.009.
22. Komohara Y, Ohnishi K, Kuratsu J et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216: 15–24.
23. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 2016; 19: 20–27. DOI:10.1038/nn.4185.
24. Mignogna C, Signorelli F, Vismara MF et al. A reappraisal of macrophage polarization in glioblastoma: histopathological and immunohistochemical findings and review of the literature. Pathol Res Pract 2016; 212: 491–499. DOI:10.1016/j.prp.2016.02.020.
25. Streit WJ, Graeber MB, Kreutzberg GW. Functional plasticity of microglia: a review. Glia 1988; 1: 301–307. DOI:10.1002/glia.440010502.
26. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S. A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun 1996; 224: 855–862. DOI:10.1006/bbrc.1996.1112.
27. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 1998; 57: 1–9. DOI:10.1016/S0169-328X(98)00040-0.
28. Korzhevskii DE, Kirik OV. Brain microglia and microglial markers. Neurosci Behav Physiol 2016; 46: 284–290. DOI:10.1007/s11055-016-0231-z.
29. Sasaki A, Nakanishi Y, Nakazato Y, Yamaguchi H. Application of lectin and B-lymphocyte-specific monoclonal antibodies for the demonstration of human microglia in formalin-fixed, paraffin-embedded brain tissue. Virchows Arch A Pathol Anat Histopathol 1991; 419: 291–299. DOI:10.1007/BF01606520.
30. Sasaki A, Horikoshi Y, Yokoo H, Nakazato Y, Yamaguchi H. Antiserum against human glucose transporter 5 is highly specific for microglia among cells of the mononuclear phagocyte system. Neurosci Lett 2003; 338: 17–20. DOI:10.1016/S0304-3940(02)01332-0.
31. Sasaki A, Nakazato Y, Ogawa A, Sugihara S. The immunophenotype of perivascular cells in the human brain. Pathol Int 1996; 46: 15–23. DOI:10.1111/j.1440-1827.1996.tb03528.x.
32. Paulus W, Roggendorf W, Kirchner T. Ki-M1P as a marker for microglia and brain macrophages in routinely processed human tissues. Acta Neuropathol 1992; 84: 538–544. DOI:10.1007/BF00304473.
33. Sasaki A, Nakazato Y. The identity of cells expressing MHC class II antigens in normal and pathological human brain. Neuropathol Appl Neurobiol 1992; 18: 13–26. DOI:10.1111/j.1365-2990.1992.tb00761.x.
34. Graeber MB, Bise K, Mehraein P. CR3/43, a marker for activated human microglia: application to diagnostic neuropathology. Neuropathol Appl Neurobiol 1994; 20: 406–408. DOI:10.1111/j.1365-2990.1994.tb00987.x.
35. Adams CW, Poston RN. Macrophage histology in paraffin-embedded multiple sclerosis plaques is demonstrated by the monoclonal pan-macrophage marker HAM-56: correlation with chronicity of the lesion. Acta Neuropathol 1990; 80: 208–211. DOI:10.1007/BF00308926.
36. Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia 2002; 40: 195–205. DOI:10.1002/glia.10148.
37. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23–35. DOI:10.1038/nri978.
38. Griffin WS, Stanley LC, Ling C et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989; 86: 7611–7615. DOI:10.1073/pnas.86.19.7611.
39. Eikelenboom P, Veerhuis R, Scheper W et al. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm (Vienna) 2006; 113: 1685–1695.
40. Mogi M, Harada M, Kondo T et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994; 180: 147–150. DOI:10.1016/0304-3940(94)90508-8.
41. Hunot S, Dugas N, Faucheux B et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999; 19: 3440–3447.
42. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994; 172: 151–154. DOI:10.1016/0304-3940(94)90684-X.
43. Sheng JG, Mrak RE, Griffin WS. Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1alpha + microglia and S100beta + astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol 1997; 56: 285–290. DOI:10.1097/00005072-199703000-00007.
44. Benzing WC, Wujek JR, Ward EK et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging 1999; 20: 581–589. DOI:10.1016/S0197-4580(99)00065-2.
45. McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 1997; 17: 2284–2294.
46. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 2007; 117: 1595–1604. DOI:10.1172/JCI31450.
47. Streit WJ, Xue QS, Braak H, del Tredici K. Presence of severe neuroinflammation does not intensify neurofibrillary degeneration in human brain. Glia 2014; 62: 96–105. DOI:10.1002/glia.22589.
48. Estes ML, McAllister AK. Alterations in immune cells and mediators in the brain: it's not always neuroinflammation! Brain Pathol 2014; 24: 623–630. DOI:10.1111/bpa.12198.
49. Pittock SJ, Debruyne J, Krecke KN et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 2010; 133: 2626–2634. DOI:10.1093/brain/awq164.
50. Kleinschmidt-DeMasters BK, West M. CLIPPERS with chronic small vessel damage: more overlap with small vessel vasculitis? J Neuropathol Exp Neurol 2014; 73: 262–267. DOI:10.1097/NEN.0000000000000050.
51. Sasaki A, Hirato J, Nakazato Y. Immunohistochemical study of microglia in the Creutzfeldt-Jakob diseased brain. Acta Neuropathol 1993; 86: 337–344. DOI:10.1007/BF00369445.
52. von Eitzen U, Egensperger R, Kösel S et al. Microglia and the development of spongiform change in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 1998; 57: 246–256. DOI:10.1097/00005072-199803000-00006.
53. Streit WJ, Xue QS, Tischer J, Bechmann I. Microglial pathology. Acta Neuropathol Commun 2014; 2: 142. DOI:10.1186/s40478-014-0142-6.
54. Fellner L, Jellinger KA, Wenning GK, Stefanova N. Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol 2011; 121: 675–693. DOI:10.1007/s00401-011-0833-z.
55. Nasu T, Tsukahara Y, Terayama K. A lipid metabolic disease-“membranous lipodystrophy”- an autopsy case demonstrating numerous peculiar membrane structures composed of compound lipid in bone and bone marrow and various adipose tissues. Acta Pathol Jpn 1973; 23: 539–559.
56. Hakola HPA. Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranpus polycystic osteodysplasia. Acta Psychiatr Scand 1972; 232 (Suppl): 1–17.
57. Bianchin MM, Capella HM, Chaves DL et al. Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol 2004; 24: 1–24. DOI:10.1023/B:CEMN.0000012721.08168.ee.
58. Neumann H, Takahashi K. Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol 2007; 184: 92–99. DOI:10.1016/j.jneuroim.2006.11.032.
59. Kiialainen A, Hovanes K, Paloneva J, Kopra O, Peltonen L. Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol Dis 2005; 18: 314–322. DOI:10.1016/j.nbd.2004.09.007.
60. Wakselman S, Béchade C, Roumier A, Bernard D, Triller A, Bessis A. Developmental neuronal death in hippocampus requires the microglial CD11b integrin and DAP12 immunoreceptor. J Neurosci 2008; 28: 8138–8143. DOI:10.1523/JNEUROSCI.1006-08.2008.
61. Sessa G, Podini P, Mariani M et al. Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur J Neurosci 2004; 20: 2617–2628. DOI:10.1111/j.1460-9568.2004.03729.x.
62. Sasaki A, Kakita A, Yoshida K et al. Variable expression of microglial DAP12 and TREM2 genes in Nasu-Hakola disease. Neurogenetics 2015; 16: 265–276. DOI:10.1007/s10048-015-0451-3.
63. Kondo T, Takahashi K, Kohara N et al. Heterogeneity of presenile dementia with bone cysts (Nasu-Hakola disease): three genetic forms. Neurol 2002; 59: 1105–1107. DOI:10.1212/WNL.59.7.1105.
64. Satoh J, Tabunoki H, Ishida T et al. Immunohistochemical characterization of microglia in Nasu-Hakola disease brains. Neuropathology 2011; 31: 363–375. DOI:10.1111/j.1440-1789.2010.01174.x.
65. Paloneva J, Autti T, Raininko R et al. CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts. Neurol 2001; 56: 1552–1558. DOI:10.1212/WNL.56.11.1552.
66. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006; 7: 1266–1273. DOI:10.1038/ni1411.
67. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009; 27: 119–145. DOI:10.1146/annurev.immunol.021908.132528.
68. Ikeuchi T. Adult-onset hereditary leukoencephalopathy: classification and molecular basis of the disorder. Rinsho Shinkeigaku 2012; 52: 1386–1389 [Article in Japanese]. DOI:10.5692/clinicalneurol.52.1386.
69. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 2004; 14: 628–638. DOI:10.1016/j.tcb.2004.09.016.
70. Otero K, Turnbull IR, Poliani PL et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and β-catenin. Nat Immunol 2009; 10: 734–744. DOI:10.1038/ni.1744.
71. Konno T, Tada M, Tada M et al. Haploinsufficiency of CSF-1R and clinicopathologic characterization in patients with HDLS. Neurology 2013; 82: 139–148. DOI:10.1212/WNL.0000000000000046.
72. Riku Y, Ando T, Goto Y et al. Early pathologic changes in hereditary diffuse leukoencephalopathy with spheroids. J Neuropathol Exp Neurol 2014; 73: 1183–1190. DOI:10.1097/NEN.0000000000000139.
73. Oyanagi K, Kinoshita M, Suzuki-Kouyana E et al. Adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and Nasu-Hakola disease: Lesion staging and dynamic changes of axons and microglial subsets. Brain Pathol 2016 Sep 8. DOI:10.1111/bpa.12443. [Epub ahead of print]
74. Guerreiro R, Hardy J. TREM2 and neurodegenerative disease. N Eng J Med 2013; 369: 1569–1570.
75. Bradshaw EM, Chibnik LB, Keenan BT et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci 2013; 16: 848–850. DOI:10.1038/nn.3435.
76. Griciuc A, Serrano-Pozo A, Parrado AR et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013; 78: 631–643. DOI:10.1016/j.neuron.2013.04.014.
77. Wu W, Tanrivermis Sayit A, Vinters HV, Pope W, Mirsadraei L, Said J. Primary central nervous system histiocytic sarcoma presenting as a postradiation sarcoma: case report and literature review. Hum Pathol 2013; 44: 1177–1183. DOI:10.1016/j.humpath.2012.11.002.
78. Grogan TM, Pileri SA, Chan JKC, Weiss LM, Fletcher CDM. Histiocytic sarcoma. In: Swerdlow SH, Campo E, Harris NL et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: International Arctic Research Center, University of Alaska, Fairbanks, 2008; 356–357.
79. Huysentruyt LC, Akgoc Z, Seyfried TN. Hypothesis: are neoplastic macrophages/microglia present in glioblastoma multiforme? ASN Neuro 2011; 3 (ii): e00064. DOI:10.1042/AN20110011.
80. Morantz RA, Wood GW, Foster M, Clark M, Gollahon K. Macrophages in experimental and human brain tumors. part 2: Studies of the macrophage content of human brain tumors. J Neurosurg 1979; 50: 305–311. DOI:10.3171/jns.1979.50.3.0305.
81. Rossi ML, Hughes JT, Esiri MM, Coakham HB, Brownell DB. Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol 1987; 74: 269–277. DOI:10.1007/BF00688191.
82. Morimura T, Neuchrist C, Kitz K et al. Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation. Acta Neuropathol 1990; 80: 287–294. DOI:10.1007/BF00294647.
83. Roggendorf W, Strupp S, Paulus W. Distribution and characterization of microglia/macrophages in human braintumors. Acta Neuropathol 1996; 92: 288–293. DOI:10.1007/s004010050520.
84. Sasaki A, Yokoo H, Tanaka Y et al. Characterization of microglia/macrophages in gliomas developed in S-100b-v-erbB transgenic rats. Neuropathology 2013; 33: 505–514. DOI:10.1111/neup.12015.
85. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166–6173. DOI:10.4049/jimmunol.164.12.6166.
86. Murray PJ, Allen JE, Biswas SK et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014; 41: 14–20. DOI:10.1016/j.immuni.2014.06.008.
87. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677–686. DOI:10.1016/j.it.2004.09.015.
88. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958–969. DOI:10.1038/nri2448.
89. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 2008; 180: 2011–2017. DOI:10.4049/jimmunol.180.4.2011.
90. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451–483. DOI:10.1146/annurev.immunol.021908.132532.
91. Zeiner PS, Preusse C, Blank AE et al. MIF receptor CD74 is restricted to microglia/macrophages, associated with a M1-polarized immune milieu and prolonged patient survival in gliomas. Brain Pathol 2015; 25: 491–504. DOI:10.1111/bpa.12194.
92. Carr A, Herpai D, Huang Y et al. TMIC-07ALDH1A2 is a candidate biomarker for M2-type macrophages in glioblastoma. Neuro Oncol 2015; 17 (Suppl 5): v215. DOI:10.1093/neuonc/nov23607.
93. Komohara Y, Horlad H, Ohnishi K et al. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci 2012; 103: 2165–2172. DOI:10.1111/cas.12015.
94. Feng X, Szulzewsky F, Yerevanian A, Chen Z et al. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. Oncotarget 2015; 6: 15077–15094. DOI:10.18632/oncotarget.3730.
95. Sasaki A, Tamura M, Hasegawa M, Ishiuchi S, Hirato J, Nakazato Y. Expression of interleukin-1beta mRNA and protein in human gliomas assessed by RT-PCR and immunohistochemistry. J Neuropathol Exp Neurol 1998; 57: 653–663. DOI:10.1097/00005072-199807000-00002.
96. Szulzewsky F, Pelz A, Feng X et al. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One 2015; 10: e0116644. DOI:10.1371/journal.pone.0116644.
97. Dudvarski Stankovic N, Teodorczyk M, Ploen R, Zipp F, Schmidt MH. Microglia-blood vessel interactions: a double-edged sword in brain pathologies. Acta Neuropathol 2016; 131: 347–363. DOI:10.1007/s00401-015-1524-y.
98. Sasaki A, Yamaguchi H, Horikoshi Y, Tanaka G, Nakazato Y. Expression of glucose transporter 5 by microglia in human gliomas. Neuropathol Appl Neurobiol 2004; 30: 447–455. DOI:10.1111/j.1365-2990.2004.00556.x.
99. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459–466. DOI:10.1016/S1470-2045(09)70025-7.
100. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003. DOI:10.1056/NEJMoa043331.
101. Hsu CY, Lin SC, Ho HL et al. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. Am J Surg Pathol 2013; 37: 264–271. DOI:10.1097/PAS.0b013e318267b061.
102. Engler JR, Robinson AE, Smirnov I et al. Increased microglia/macrophage Gene expression in a subset of adult and pediatric astrocytomas. PLoS One 2012; 7: e43339. DOI:10.1371/journal.pone.0043339.
103. Platten M, Kretz A, Naumann U et al. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 2003; 54: 388–392. DOI:10.1002/ana.10679.
104. Okada M, Saio M, Kito Y et al. Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int J Oncol 2009; 34: 1621–1627.
105. Badie B, Schartner J, Klaver J, Vorpahl J. In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. Neurosurg 1999; 44: 1077–1082. DOI:10.1097/00006123-199905000-00075.
106. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71–82. DOI:10.1016/S1074-7613(03)00174-2.
107. Yona S, Kim KW, Wolf Y et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013; 38: 79–91. DOI:10.1016/j.immuni.2012.12.001.
108. Lavin Y, Winter D, Blecher-Gonen R et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 2014; 159: 1312–1326. DOI:10.1016/j.cell.2014.11.018.
109. Hirano H, Tanioka K, Yokoyama S, Akiyama S, Kuratsu J. Angiogenic effect of thymidine phosphorylase on macrophages in glioblastoma multiforme. J Neurosurg 2001; 95: 89–95. DOI:10.3171/jns.2001.95.1.0089.
110. Jenny B, Harrison JA, Baetens D et al. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol 2006; 209: 34–43. DOI:10.1002/path.1943.
111. Wei J, Gabrusiewicz K, Heimberger A. The controversial role of microglia in malignant gliomas. Clin Dev Immunol 2013; 2013: 285246. DOI:10.1155/2013/285246.
112. Stefanik DF, Fellows WK, Rizkalla LR et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 2001; 55: 91–100. DOI:10.1023/A:1013329832067.
113. Yi L, Xiao H, Xu M et al. Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma. J Neuroimmunol 2011; 232: 75–82. DOI:10.1016/j.jneuroim.2010.10.011.
114. Pyonteck SM, Akkari L, Schuhmacher AJ et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19: 1264–1272. DOI:10.1038/nm.3337.
115. Frazier JL, Wang PP, Case D et al. Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. J Neurooncol 2003; 64: 203–209. DOI:10.1023/A:1025695423097.
116. Zhou W, Ke SQ, Huang Z et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol 2015; 17: 170–182. DOI:10.1038/ncb3090.
117. Sierra A, Abiega O, Shahraz A, Neumann H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front Cell Neurosci 2013; 7: 6. DOI:10.3389/fncel.2013.00006.
118. Graeber MB. Changing face of microglia. Science 2010; 330: 783–788. DOI:10.1126/science.1190929.
119. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 2009; 29: 3974–3980. DOI:10.1523/JNEUROSCI.4363-08.2009.
120. Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell 2014; 158: 15–24. DOI:10.1016/j.cell.2014.06.008.